The relationship between valproate induced tremors and circulating neurotransmitters: a preliminary study

References

• Hyman NM, Dennis PD, Sinclair KG. Tremor due to sodium valproate. Neurology 1979;29(8):1177–80. PMID: 379690.
   PubMed Web of Science ®Google Scholar
• Karas BJ, Wilder BJ, Hammond EJ, et al. Valproate tremors. Neurology 1982;32(4):428–32. PMID: 6801541.
   PubMed Web of Science ®Google Scholar
• van der Zwan A Jr. Transient Parkinson syndrome and tremor caused by the use of sodium valproate. Ned Tijdschr Geneeskd 1989;133(24):1230–2. PMID: 2501690.
   PubMedGoogle Scholar
• Mehndiratta MM, Satyawani M, Gupta S, et al. Clinical and surface EMG characteristics of valproate induced tremors. Electromyogr Clin Neurophysiol 2005;45(3):177–82. PMID: 15981690.
   PubMedGoogle Scholar
• Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007;78(2):147–51. PMID: 17012337.
   PubMed Web of Science ®Google Scholar
• Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993;16(5):451–5. PMID: 8221706.
   PubMed Web of Science ®Google Scholar
• Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996;47(3):626–35. PMID: 8797455.
   PubMed Web of Science ®Google Scholar
• Park-Matsumoto YC, Tazawa T. Valproate induced parkinsonism. No To Shinkei 1998;50(1):81–4. PMID: 9493204.
   PubMedGoogle Scholar
• Onofrj M, Thomas A, Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol 1998;245(12):794–6. PMID: 9493204.
   PubMed Web of Science ®Google Scholar
• Nouzeilles M, García M, Rabinowicz A, et al. Prospective evaluation of parkinsonism and tremor in patients treated with valproate. Parkinsonism Relat Disord 1999;5(1–2):67–8. PMID: 18591122.
   PubMed Web of Science ®Google Scholar
• Masmoudi K, Gras-Champel V, Bonnet I, et al. Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie 2000;55(5):629–34. PMID: 11201978.
   PubMed Web of Science ®Google Scholar
• Easterford K, Clough P, Kellett M, et al. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004;62(8):1435–7. PMID: 15111693.
   PubMed Web of Science ®Google Scholar
• Ricard C, Martin K, Tournier M, et al. A case of parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale 2005;31(1 Pt 1):98–101. PMID: 15971646.
   PubMed Web of Science ®Google Scholar
• Ristić AJ, Vojvodić N, Janković, S, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006;47(12):2183–5. PMID: 17201721.
   PubMed Web of Science ®Google Scholar
• Masmoudi K, Gras-Champel V, Masson H, et al. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006;39(1):9–12. PMID: 16453247.
   PubMed Web of Science ®Google Scholar
• Jamora D, Lim SH, Pan A, et al. Valproate-induced parkinsonism in epilepsy patients. Mov Disord 2007;22(1):130–3. PMID: 17115396.
   PubMed Web of Science ®Google Scholar
• Schreur L, Middeljans-Tijssen CW, Hengstman GJ, et al. Cognitive impairment and parkinsonism due to use of sodium valproate. Tijdschr Gerontol Geriatr 2009;40(1):29–33. PMID: 19326700.
   PubMedGoogle Scholar
• Silver M, Factor SA. Valproic acid-induced parkinsonism: levodopa responsiveness with dyskinesia. Parkinsonism Relat Disord 2013;19(8):758–60. PMID: 23632325.
   PubMed Web of Science ®Google Scholar
• Bodensteiner JB, Morris HH, Golden GS. Asterixis associated with sodium valproate. Neurology 1981;31(2):194–5. PMID: 6780925.
   PubMed Web of Science ®Google Scholar
• Lancman ME, Asconapé JJ, Penry JK. Choreiform movements associated with the use of valproate. Arch Neurol 1994;51(7):702–4. PMID: 8018044.
   PubMedGoogle Scholar
• Kanner AM, Balabanov A. Valproate: a practical review of its uses in neurological and psychiatric disorders. Expert Rev Neurother 2002;2(2):151–65. PMID: 19810997.
   PubMedGoogle Scholar
• Schank JR, Liles LC, Weinshenker D. Reduced anticonvulsant efficacy of valproic acid in dopamine beta-hydroxylase knockout mice. Epilepsy Res 2005;65(1–2):23–31. PMID: 15955669.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Onem E, Patel P, et al. Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation. Brain Res 2009;1247:1–10. PMID: 18976638.
   PubMed Web of Science ®Google Scholar
• Proposal for revised classification of epilepsies and epileptic syndromes: from the commission on classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30(4):389–99. PMID: 2502382.
   PubMed Web of Science ®Google Scholar
• Louis ED, Ford B, Lee H, et al. Diagnostic criteria for essential tremor: a population perspective. Arch Neurol 1998;55(6):823–8. PMID: 9626774.
   PubMedGoogle Scholar
• Hamed SA, Hamed EA, Kandil MR, et al. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res 2005;66(1–3):173–83. PMID: 16169189.
   PubMed Web of Science ®Google Scholar
• Dugas M, Brunod R, Masson M. Tremor in the course of sodium valproate treatment. Nouv Presse Med 1981;10(34):2828. PMID: 6796937.
   PubMedGoogle Scholar
• Lewitt PA. Tremor induced or enhanced by pharmacological means. In: Findley LJ, Koller WC, eds. Handbook of tremor disorders. New York: Dekker; 1995:473–81.
   Google Scholar
• Rinnerthaler M, Luef G, Mueller J, et al. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. Epilepsia 2005;4692:320–3. PMID: 15679514.
   Web of Science ®Google Scholar
• McCabe PH, Michel NC, McNew CD, et al. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. Epilepsy Behav 2006;8(3):601–5. PMID: 16678766.
   PubMed Web of Science ®Google Scholar
• Pierre-Louis SJ, Brannegan RT, Evans AT. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium. Clin Neurol Neurosurg 2009;111(5):437–41. PMID: 19181439.
   PubMed Web of Science ®Google Scholar
• Smith MC, Centorrino F, Welge JA, et al. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 2004;5(5):746–51. PMID: 15380129.
   PubMed Web of Science ®Google Scholar
• Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2002;30(5):194–202. PMID: 17408759.
   Web of Science ®Google Scholar
• Isaias IU, Marzegan A, Pezzoli G, et al. A role for locus coeruleus in Parkinson tremor. Front Hum Neurosci 2012;5:179. PMID: 22287946.
   PubMed Web of Science ®Google Scholar
• Lewitt PA. Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl Neurodegener 2012;1(1):1–4. PMID: 23211006.
   PubMedGoogle Scholar
• Dorszewska J, Prendecki M, Oczkowska A, et al. Polymorphism of the COMT, MAO, DAT, NET and 5-HTT genes, and biogenic amines in Parkinson's disease. Curr Genomics 2013;14(8):518–33. PMID: 24532984.
   PubMed Web of Science ®Google Scholar
• Hamed SA, Elserogy YE, Abd-ElHafeez HA. Psychopathological and peripheral level of neurobiological correlates of obsessive compulsive symptoms with epilepsy: a hospital-based study. Epilepsy Behav. 2013;27(2):409–15. PMID: 23541859.
   PubMed Web of Science ®Google Scholar
• Kralic JE, Criswell HE, Osterman JL, et al. Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest 2005;115(3):774–9. PMID: 15765150.
   PubMed Web of Science ®Google Scholar
• Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989;501(1):198–203. PMID: 2508993.
   PubMed Web of Science ®Google Scholar
• Vemos E, Csati A, Vecsei L, et al. Effects of valproate on the dopaminergic system in mice. Neurol Res 2009;31(3):217–9. PMID: 18768113.
   PubMed Web of Science ®Google Scholar
• Selikhova MV, Kogan BM, Serkin GV, et al. Catecholamine metabolism in different forms of Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova 2002;102(9):37–40. PMID: 12378880.
   PubMedGoogle Scholar
• Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord 2007;13(2):67–76. PMID: 16887374.
   PubMed Web of Science ®Google Scholar
• Tan EK, Lee SS, Fook-Chong S, et al. Evidence of increased odds of essential tremor in Parkinson's disease. Mov Disord 2008;23(7):993–7. PMID: 18383536.
   PubMed Web of Science ®Google Scholar
• Kolasiewicz W, Kuter K, Nowak P, et al. Lesion of the cerebellar noradrenergic innervation enhances the harmaline-induced tremor in rats. Cerebellum 2011;10(2):267–80. PMID: 21279489.
   PubMed Web of Science ®Google Scholar
• Karas BJ, Wilder BJ, Hammond EJ, et al. Treatment of valproate tremors. Neurology 1983;33(10):1380–2. PMID: 6412157.
   PubMed Web of Science ®Google Scholar
• Young R, Glennon RA. S(-)Propranolol as a discriminative stimulus and its comparison to the stimulus effects of cocaine in rats. Psychopharmacology (Berl) 2009;203(2):369–82. PMID 18795268.
   PubMed Web of Science ®Google Scholar
• Crosby NJ, Deane K, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database Systematic Rev 2003. PMID: 12535476. doi:10.1002/14651858.CD003468.
   Google Scholar